| Abstract | Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics have limited efficacy and are associated with treatment-limiting adverse events, while oral atypical antipsychotics have not improved adherence substantially. A long-acting formulation of risperidone, an atypical antipsychotic with proven efficacy, has been developed. Introduction of long-acting injectable treatment may be appropriate during inpatient hospitalization, when consequences of relapse are most evident. To support this intervention, a subanalysis of patients who were inpatients at study initiation was conducted from a 12-week, double-blind, placebo-controlled long-acting risperidone study (N = 214). Long-acting risperidone was associated with a significant reduction in total Positive and Negative Syndrome Scale (PANSS) score (mean change +/- standard error [S.E.] at endpoint: long-acting risperidone, -9.27 +/- 1.44, n = 133; placebo, 0.72 +/- 2.59, n = 41; P < 0.001), and a significantly higher rate of treatment response, defined as > or = 20% reduction in total PANSS score (50% vs. 27%, P < 0.05). Significantly more long-acting risperidone patients had endpoint Clinical Global Impressions (CGI) assessments of not ill, very mild or mild (32% vs. 5%; P < 0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia. |
| Authors | John Lauriello, Joseph P McEvoy, Stephen Rodriguez, Cynthia A Bossie, Robert A Lasser
(Affiliation: Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131-001, USA. jlauriello at salud.unm.edu)
|
| Journal | Schizophrenia research
(Schizophr Res)
Vol. 72
Issue 2-3
Pg. 249-58
(Jan 1 2005)
ISSN: 0920-9964 Netherlands |
| PMID | 15560969
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antipsychotic Agents
- Delayed-Action Preparations
- Risperidone
|
| Topics |
- Adolescent
- Adult
- Antipsychotic Agents
(administration & dosage, therapeutic use)
- Delayed-Action Preparations
(therapeutic use)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Hospitalization
- Hospitals, Psychiatric
- Humans
- Male
- Middle Aged
- Recurrence
- Risperidone
(administration & dosage, therapeutic use)
- Schizophrenia
(drug therapy, rehabilitation)
|
